BMS to present new overall survival data for Opdivo as monotherapy and in combination with Yervoy at AACR 2016 Annual Meeting

New, pivotal Phase III overall survival data from CheckMate -141 for Opdivo in previously treated advanced squamous cell carcinoma of the head and neck, to be presented.

Data to be presented for Opdivo, as a single-agent and in combination with Yervoy, illustrate the company’s commitment to expanding its Immuno-Oncology research portfolio to include additional tumour types and developing treatment options that have the potential to extend survival in hard-to-treat cancers in broad patient populations.

Jean Viallet, MD, Global Clinical Research Lead, Oncology, BMS, commented: “At this year’s AACR, we are excited to present, for the first time, overall survival data from the first pivotal Phase III trial of an Immuno-Oncology agent, Opdivo, in previously treated squamous cell carcinoma of the head and neck, a cancer that has had very few treatment advances over the past 10 years. These head and neck cancer data represent the fifth tumour type with overall survival data for Opdivo compared to a standard of care. We will also be presenting overall survival data from CheckMate -069, which was the first randomized trial to evaluate the Opdivo + Yervoy Regimen in the first-line setting for advanced melanoma, and has been a foundational study in building our scientific understanding of combining these two Immuno-Oncology agents to treat this form of cancer.”

Key data presentations include